Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IFNAR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IFNAR2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation critical for Type I IFN binding. |
View IFNAR2 Products |
| Gene Delivery | IFNAR2 Lentivirus Premade Particles Full-length ORF for stable cell line construction. High titer (>10^8 TU/mL). Puromycin selection marker. |
View IFNAR2 Products |
| Ligand | IFN-alpha2a Recombinant Protein Human Type I Interferon for binding/neutralization assays. Theoretical MW verified. |
View IFNAR2 Products |
| Benchmark Ab | Anti-IFNAR2 Reference Antibody Recombinant positive control for receptor blockade and competition assays. |
View IFNAR2 Products |
| Validator | IFNAR2 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. Sequence-verified. |
View IFNAR2 Products |
| Related Target: IFNAR1 | IFNAR1 ECD-Fc / Full-length Lentivirus Heterodimer partner essential for functional Type I IFN receptor complex formation. |
View IFNAR1 Products |
| Related Target: TYK2 | TYK2 Recombinant Protein (Kinase Domain) Downstream signaling node associated with JAK-STAT pathway analysis. |
View TYK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimeric receptor complex formation (IFNAR1/IFNAR2) | Matched pair IFNAR1 & IFNAR2 ECD-Fc proteins with verified 1:1 stoichiometry binding capability |
| Species cross-reactivity (Mouse/Cyno/Human translation) | Ortholog protein panel: Human, Cyno, Mouse IFNAR2 ECD (>95% purity, sequence verified by Mass Spec) |
| Glycosylation-dependent binding integrity | HEK293 expression system ensuring native N-glycosylation patterns critical for interferon recognition |
| Receptor internalization & trafficking studies | Full-length IFNAR2 Lentivirus for stable cell line generation (Flow cytometry compatible) |
| Cytokine receptor family selectivity | Homolog panel: IFNGR1, IL10RA, IL28RA for counter-screening against off-target binding |
Live IFNAR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The IFNAR2 target represents a pivotal node in the Type I Interferon signaling axis, historically validated through decades of IFN-beta therapy in Multiple Sclerosis. Current R&D is pivoting from broad cytokine administration to precision receptor modulation. The competitive landscape is bifurcating between direct IFNAR2-blocking strategies for autoimmune indications (SLE, dermatomyositis) and decoy receptor approaches that sequester pathogenic interferons while preserving beneficial antiviral responses.
As first-generation biologics mature, the next wave of innovation focuses on subcutaneous high-concentration formulations, heterodimer-disrupting bispecifics (IFNAR1/IFNAR2), and combination regimens with JAK inhibitors to circumvent downstream resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor / Fc-Fusion | Biogen, Roche, AC Immune | MS, SLE, Viral infections | IFN binding affinity (ECD-Fc), Neutralization potency vs IFN-alpha/beta |
| Blocking mAb | Specialty Biotechs (IFNAR2 selective) | SLE, Type I Interferonopathies | Heterodimer disruption assay (IFNAR1/IFNAR2), Ligand competition |
| Recombinant Cytokine | Merck (Rebif), Biogen (Plegridy), Novartis | Relapsing MS | Receptor binding kinetics, Differential affinity to IFNAR2 vs IFNAR1 |
| Bispecific Decoy | Emerging Biotechs | COVID-19, Autoimmune | Dual cytokine capture (IFNAR2 ECD paired with IFNAR1 binding) |